• Appointed new non-executive director, announced passing of previous director
• Expanded Nasodine distribution and marketing in Singapore and Southeast Asia
• Raised $1.4 million in placement, received $0.25 million R&D tax incentive

Firebrick Pharma Ltd (ASX:FRE) provided its business activity update for the quarter ending 30 September 2025, along with its Appendix 4C quarterly cashflow report. Key updates include the appointment of Rick Legleiter as a new non-executive director and the passing of previous director Dr Phyllis Gardner. The company is currently seeking an additional non-executive director. On the marketing front, Firebrick executed a License and Distribution Agreement with Innorini Pte Ltd covering sales of Nasodine products in Singapore, Malaysia, Brunei, and Mauritius. This extends Innorini's responsibilities from healthcare professional marketing to include retail sales initiatives in Singapore and sub-licensing and distribution in the additional countries. From a financial perspective, operating cash costs increased around 9% primarily due to a new batch of Nasodine production and increased regulatory filing costs, partly offset by reduced staff and marketing expenses. The company announced a $1.4 million placement to fund several projects, including expanding Nasodine sales in the US, distribution and marketing in Singapore, and the launch of new Nasodine-brand products. Firebrick also received $0.25 million in R&D tax incentive income. The company ended the quarter with $1.94 million in cash reserves, providing more than 12 months' ongoing funding for operations.